Introduction {#Sec1}
============

Populations are rapidly aging worldwide. This is particularly true in Japan, where there is an increased need to address problems associated with the aging population \[[@CR1], [@CR2]\]. One consequence of population aging is an increase in the number of elderly patients with diabetes mellitus \[glycated hemoglobin A1c (HbA1c) ≥ 6.5%\] \[[@CR3]\]. A Japanese nationwide survey reported an increase in the prevalence of diabetes mellitus with advancing age, and diabetes mellitus was suspected in approximately 23% of men and 12% of women aged ≥60 years \[[@CR3]\]. These patients often have atherosclerotic complications \[[@CR4], [@CR5]\], and diabetes prevention and management are strongly desired to promote health and reduce the impact on healthcare expenditure.

Diabetes treatment guidelines that recommend intensive multifactorial interventions to prevent macro- and microcomplications have been established for young and middle-aged patients with diabetes \[[@CR5]\]. However, treatment strategies for elderly patients with diabetes are not well established, and treatment goals for glycemic control are controversial because of insufficient accumulated clinical evidence and difficulties associated with intensive therapy in elderly patients \[[@CR4]--[@CR6]\]. Of particular concern, intensive treatment in elderly patients with diabetes may increase risk of death \[[@CR7]\], falls \[[@CR8]\], and cognitive function decline \[[@CR9]\] due to hypoglycemic events. Therefore, glycemic control targets should depend on individual patient characteristics, for example, the newest position statement recommends lower glycemic control targets (HbA1c \< 6.5--7.0%) for healthy elderly patients, while an HbA1c \< 7.0--8.0% may be acceptable if lower targets cannot be achieved \[[@CR6]\].

Regardless of these concerns, comprehensive management to prevent atherosclerotic complications requires the achievement of adequate glycemic control in elderly as well as non-elderly patients with diabetes \[[@CR4], [@CR5]\]. Unfortunately, only a few studies have evaluated the safety and efficacy of comprehensive management in elderly patients \[[@CR10]\]. The current study was an age-specific evaluation of the effectiveness and safety of newly initiated insulin therapy over a 1-year period in elderly (≥65 years) and non-elderly (≤64 years) Japanese patients with uncontrolled diabetes, incorporating comprehensive management with SMBG.

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

The present study was a retrospective cohort study conducted at a specialist medical clinic for diabetes treatment in Fukushima, Japan. We surveyed all outpatients with diabetes who visited the clinic for diabetes treatment from December 2006 to March 2011. Study participants were then selected from those patients who were initiated on insulin therapy during the study period, including those whose medication was modified from oral hypoglycemic agents to insulin therapy and those who were prescribed insulin as add-on therapy due to continued poor glycemic control, defined as HbA1c \[National Glycohemoglobin Standardization Program (NGSP)\] \[[@CR11]\] ≥8.0% for at least 3 months \[calculated using the following formula: HbA1c (NGSP, %) = 1.02 × HbA1c (Japan Diabetes Society \[JDS\]) + 0.25%\]. Patients with concomitant chronic diseases such as kidney dysfunction (plasma creatinine ≥ 2 mg/dL), severe cardiovascular disease, severe cognitive dysfunction, poor nutritional condition, and type 1 diabetes mellitus were excluded from the study.

There were three certified diabetes educators and one dietitian in the medical clinic. The attending physician determined the patients' insulin therapy strategies, taking into consideration diabetic control status, comorbidities, and family support. A certified diabetes educator then met with the patient to instruct him or her in the use of insulin devices and SMBG. Patients were instructed to measure their blood glucose concentration twice each day (before breakfast and dinner). After initiation of insulin therapy, and at monthly medical consultations, the attending physician checked the patient's HbA1c levels and SMBG records, and modified their medications as necessary. The certified diabetes educator also checked the use of insulin devices and SMBG procedures every 2 or 3 months. The dietitian met all patients to evaluate their dietary behavior and to provide diabetic dietary advice once or twice a year.

Variables {#Sec4}
---------

Baseline clinical data at initiation of insulin therapy were obtained from the patients' medical files. Data collection was conducted from November 2012 to February 2013 by three office staff at the medical clinic. The following demographic data were collected: age, sex, height, weight, family history (hypertension, diabetes mellitus, heart disease, and cerebrovascular disease), presence of micro- and macrovascular diseases \[diabetic neuropathy (sensory symptoms present, absent ankle reflexes, inability to sense vibration), diabetic retinopathy, diabetic nephropathy (present micro- and/or macroalbuminuria), cardiovascular disease, and cerebrovascular disease\], alcohol consumption, and smoking status. To assess blood pressure related items, we collected information on systolic and diastolic blood pressure, and medication history for hypertension. We also collected total cholesterol (mg/dL; TC), high-density lipoprotein cholesterol (mg/dL; HDL-C), low-density lipoprotein cholesterol (mg/dL; LDL-C), triglyceride (mg/dL; TG), and medication history for hyperlipidemia. LDL-C was estimated using the Friedwald equation \[(TC) -- (HDL-C) -- (TG/5)\] \[[@CR12]\]. These were baseline data before initiation of insulin therapy, and also collected retrospectively from medical files.

The following diabetes-related information was collected as baseline data: just the latest HbA1c measurement before initiation of insulin therapy, type of insulin initiated, insulin dosage per day, and type of oral hypoglycemic agent used. HbA1c levels were determined by high-performance liquid chromatography using an automated analyzer (Arkray, Kyoto, Japan).

HbA1c was measured and hypoglycemic events were checked every month. We collected follow-up data from medical records: HbA1c measurements at 3, 6, and 12 months after initiation of insulin therapy, including bodyweight change and insulin dosage at 12 months, and adverse effects including severe hypoglycemic events and withdrawal from insulin therapy. Body weight also measured every month, and lipid-related measurements were measured every 3 or 4 months. In the analysis, we used baseline data and data at 12 months.

This survey was conducted according to the Ethical Guidelines for Epidemiological Studies established by the Japanese government \[[@CR13]\], and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. The Ethics Committee of Juntendo University approved the research protocol (No. 832). Informed consent was obtained from all patients for being included in the study.

Statistical Analysis {#Sec5}
--------------------

Primary endpoint of the study was HbA1c levels after initiation of insulin therapy and secondary endpoint was severe hypoglycemic complications. Participants were categorized into two age categories: elderly patients (≥65 years) and non-elderly patients (≤64 years). The Mann--Whitney test for continuous variables and the Chi-square test for categorical variables were used to compare the two groups. For paired analysis, the Wilcoxon signed-rank test was used for continuous variables. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for Social Sciences version 19 (SPSS Inc., Chicago, IL, USA).

Results {#Sec6}
=======

Patients {#Sec7}
--------

During the study period, 132 patients with type 2 diabetes began insulin therapy at the medical clinic. Thirty-two of these patients were excluded from the current study based on exclusion criteria (4), lack of data (13), or were lost to follow-up (15). The remaining 100 patients were enrolled in the study. Baseline characteristics of these participants are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the study participants (*N* = 100)Median (range) or *N* (%)*P* valueNon-elderly, ≤64 years (*N* = 67)Elderly, ≥65 years (*N* = 33)Age (years)*52* (*19*, *64*)*69* (*65*, *84*)\<0.01Sex (male)46 (68.7)22 (66.7)0.84Anthropometric measurements BMI (kg/m^2^)*24.0* (*18.0*, *35.8*)*23.0* (*19.2*, *29.5*)0.09 BMI ≥ 25 kg/m^2^*27* (*40.3*)*10* (*30.3*)0.09 Waist circumference (cm)  Male*86.0* (*63.9*, *105.5*)*89.9* (*74.5*, *99.0*)0.53  Female*82.0* (*66.7*, *114.0*)*73.0* (*70.0*, *94.5*)0.12Family history (present) Diabetes mellitus41 (61.2)17 (51.5)0.36 Hypertension6 (9.0)2 (6.1)0.62 Cerebrovascular disease1 (1.5)0 (0.0)0.48 Heart disease1 (1.5)0 (0.0)0.48Lifestyle characteristics Alcohol consumption (everyday drinker)8 (11.9)4 (12.1)0.81 Smoking behavior (current smoker)20 (29.9)6 (18.2)0.24Complications (present) Diabetic neuropathy31 (46.3)25 (75.8)\<0.01 Diabetic retinopathy7 (10.4)6 (18.2)0.35 Diabetic nephropathy33 (49.3)18 (54.5)0.62 Cardiovascular complications37 (55.2)15 (45.5)0.36 Cerebrovascular complications42 (62.7)16 (48.5)0.18Hypertension-related factors Systolic blood pressure (mmHg)*135* (*91*, *185*)*140* (*98*, *175*)0.24 Diastolic blood pressure (mmHg)*85* (*47*, *107*)*72* (*47*, *95*)\<0.01 Antihypertensive drug use (yes)18 (26.9)19 (57.6)\<0.01Lipid-related parameters High-density lipoprotein cholesterol (mg/dL)*53* (*28*, *116*)*56* (*29*, *114*)0.87 Low-density lipoprotein cholesterol (mg/dL)*120.0* (*65.0*, *291.0*)*111.6* (*61.4*, *188.0*)0.14 Triglycerides (mg/dL)*149* (*56*, *819*)*116* (*39*, *973*)0.04 Antidyslipidemic drug use (yes)17 (25.4)12 (36.4)0.23Diabetes-related items Duration of diabetic treatment (years)*7.5* (*0.5*, *24*)*12* (*0.5*, *35*)\<0.01 Hemoglobin A1c (%) at baseline*10.8* (*8.0*, *17.1*)*9.6* (*8.1*, *13.9*)\<0.01 Treatment of diabetes mellitus  Sulfonylurea28 (41.8)22 (66.7)0.02  Alpha glucosidase inhibitor10 (14.9)6 (18.2)0.68  Biguanides13 (19.4)13 (39.4)0.03  Thiazolidine derivatives17 (25.4)11 (33.3)0.40  DPP-4 inhibitor1 (1.5)2 (6.1)0.21 Number of oral glucose lowering drugs  033 (49.3)9 (27.3)0.08  111 (16.4)4 (12.1)  211 (16.4)11 (33.3)  312 (17.9)8 (24.2)  40 (0.0)1 (3.0) Type of insulin at initiation  Ultra-rapid insulin42 (62.7)5 (15.2)\<0.01  Rapid-acting insulin0 (0.0)5 (15.2)\<0.01  Mixed insulin16 (23.9)4 (12.1)0.17  Long-acting insulin14 (20.9)20 (60.6)\<0.01 Insulin dosage at initiation (U/day)18 (8, 34)10 (6, 24)\<0.01*P* \< 0.05 was considered statistically significantThe Mann--Whitney test for continuous variables and the Chi-square test for categorical variables were used to compare the two groups*BMI* body mass index

Of the 100 participants, 33 (33.0%) were elderly (≥65 years) and 67 (67.0%) were non-elderly. Median age among the elderly and non-elderly patients was 69 years (range 65--84) and 52 years (range 19--64; *P* \< 0.01), respectively. The proportions of male patients were 66.7% and 68.7%, respectively. Median BMIs of the elderly and non-elderly patients were 23.0 kg/m^2^ (19.2--29.5) and 24.0 kg/m^2^ (18.0--35.8), respectively. Antihypertensive drug use was significantly more frequent (57.6% vs 26.9%, *P* \< 0.01) and diabetic neuropathy was more common (75.8% vs 46.3%, *P* \< 0.01) among elderly compared to non-elderly patient.

At baseline, elderly patients were prescribed sulfonylureas and biguanides to treat diabetes more frequently than non-elderly patients (Table [1](#Tab1){ref-type="table"}). After initiation of insulin therapy, non-elderly patients were more likely to be treated with ultra-rapid insulin (62.7% vs 15.2%, *P* \< 0.01), while elderly patients were more likely to be treated with long-acting insulin (20.9% vs 60.6%, *P* \< 0.01). No severe hypoglycemic complications were observed in either group during the study period; insulin therapy was stopped in 3 elderly (9.1%) and 10 non-elderly (14.9%) patients because of improvements in their glycemic control.

Glycemic Control {#Sec8}
----------------

Changes from baseline in glycemic control, lipid profiles, body weight, and insulin dosage are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. In the non-elderly patient group, HbA1c levels were significantly improved at 3 (*P* \< 0.01), 6 (*P* \< 0.01) and 12 months (*P* \< 0.01) after initiation of insulin therapy, and reached 7.3% (range 6.0--12.0) at 12 months \[−3.8% (−11.4, 0.9), *P* \< 0.01\]. However, median insulin dosage \[5 U/day (−10, 23)\] and median body weight were significantly higher at 12 months \[4.2 kg (−20.2, 11.6), *P* \< 0.01; Table [2](#Tab2){ref-type="table"}\]. For elderly patients, HbA1c levels were significantly improved at 3 (*P* \< 0.01), 6 (*P* \< 0.01) and 12 months (*P* \< 0.01) after initiation of insulin therapy, and HbA1c levels and reached \[7.2% (6.0, 9.9), −2.5% (−6.4, −1.3), *P* \< 0.01\] at 12 months. Insulin dosage increased \[6 (−4, 21), *P* \< 0.01\], but changes in body weight were not significant \[2.8 (−8.2, 13.49), *P* = 0.10; Table [3](#Tab3){ref-type="table"}\]. Lipid profiles did not change significantly from baseline in either group at 12 months compared to baseline (Table [2](#Tab2){ref-type="table"}).Table 2Changes in glycemic control and lipid profiles during the 12 months after insulin therapy initiation among non-elderly participants (≤64 years, *N* = 67)Median (range) or *N* (%)Baseline3 months*P* value6 months*P* value12 months*P* valueHemoglobin A1c (%)10.8 (8.0, 17.1)8.2 (6.0, 14.0)\<0.017.3 (5.4, 10.9)\<0.017.3 (6.0, 12.0)\<0.01 Change in hemoglobin A1c (%)−3.8 (−11.4, 0.9)Low-density lipoprotein cholesterol (mg/dL)120.0 (65.0, 291)----114.2 (48.0, 199.0)0.05High-density lipoprotein cholesterol (mg/dL)53.0 (28.0, 116.0)----51.0 (31.0, 87.0)0.49Triglycerides (mg/dL)149 (56, 819)----146 (41, 655)0.27Body weight (kg)66.1 (46.0, 97.6)----68.8 (49.1, 96.8)\<0.01 Change in body weight (kg)4.2 (−20.2, 11.6)Insulin dosage (U/day)18 (8, 34)22 (6, 52)\<0.0121 (6, 54)\<0.0120 (8, 48)\<0.01 Change in insulin dosage (U/day)5 (−10, 23)Freedom from insulin therapy (yes)------10 (14.9)Severe hypoglycemic complication (yes)------0 (0.0)The Wilcoxon signed-rank test was used for paired analyses to compare to baseline dataTable 3Change in glycemic control and lipid profiles during the 12 months after insulin therapy initiation among elderly participants (≥65 years, *N* = 33)Median (range) or *N* (%)Baseline3 months*P* value6 months*P* value12 months*P* valueHbA1c (%)9.6 (8.1, 13.9)7.9 (6.4, 10.6)\<0.017.3 (6.2, 9.1)\<0.017.2 (6.0, 9.0)\<0.01 Change in HbA1c (%)−2.5 (−6.4, −1.3)Low-density lipoprotein cholesterol (mg/dL)111.6 (61.4, 188.0)----105.8 (58.0, 165.0)0.08High-density lipoprotein cholesterol (mg/dL)55.6 (29.0, 114.0)----55.5 (22.0, 110.0)0.81Triglycerides (mg/dL)116 (39, 973)----109 (50, 289)0.05Body weight (kg)62.0 (43.0, 78.6)----63.2 (41.9, 85.4)0.10 Change in body weight (kg)2.8 (−8.2, 13.4)Insulin dosage (U/day)10 (6, 24)16 (5, 40)\<0.0118 (5, 42)\<0.0118 (8, 40)\<0.01 Change in insulin dosage (U/day)6 (−4, 21)Freedom from insulin therapy (yes)------3 (9.1)Severe hypoglycemic complication (yes)------0 (0.0)The Wilcoxon signed-rank test was used for paired analyses to compare to baseline data*HbA1c* glycated hemoglobin

Figure [1](#Fig1){ref-type="fig"} shows HbA1c levels for elderly and non-elderly patients after a follow-up period of 1 year. After initiation of insulin therapy, diabetes remained uncontrolled (HbA1c ≥ 8%) in 31.8% of non-elderly and 15.4% of elderly patients (*P* = 0.08). In the patient population overall, 26 patients (26.0%) had uncontrolled diabetes and was more frequently in obese patients (BMI ≥ 25 kg/m^2^) compared to patients with HbA1c \< 8% after 1 year (64.9% vs 76.9%, *P* = 0.04) (Table [4](#Tab4){ref-type="table"}).Fig. 1Distribution of hemoglobin A1c (HbA1c) levels at 1-year follow-upTable 4Baseline characteristics of participants with controlled and uncontrolled diabetes after 1-year follow-upMedian (range) or *N* (%)*P* valueControlled group, HbA1c \< 8% (*N* = 74)Uncontrolled group, HbA1c ≥ 8% (*N* = 26)Proportion of elderly participants (≥65 years)28 (37.8)5 (19.2)0.08Sex (male)48 (64.9)20 (76.9)0.04BMI ≥ 25 kg/m^2^23 (31.1)14 (53.8)0.04BMI (kg/m^2^)*23.1* (*18.0*, *35.8*)*25.4* (*18.4*, *33.3*)0.07Lifestyle characteristics Alcohol consumption (everyday drinker)11 (30.6)1 (7.7)0.10 Smoking behavior (current smoker)21 (32.3)5 (20.0)0.25Antihypertensive drug use (yes)29 (39.2)8 (30.8)0.44Antidyslipidemic drug use (yes)52 (72.2)9 (34.6)0.51Diabetic complications (present)52 (70.3)20 (76.9)0.52Macrovascular complications (present)56 (74.0)17 (65.4)0.31*P* \< 0.05 was considered statistically significantThe Mann--Whitney test for continuous variables and the Chi-square test for categorical variables were used to compare between controlled and uncontrolled group at 12 months*BMI* body mass index, *HbA1c* glycated hemoglobin

Discussion {#Sec9}
==========

This retrospective cohort survey conducted at one medical clinic in Japan revealed the effectiveness of intensive insulin therapy for elderly Japanese patients (≥65 years) with uncontrolled diabetes mellitus, demonstrating an improvement in glycemic control 1 year after initiation of insulin therapy that was comparable to that observed in non-elderly patients (\<65 years). In addition, severe hypoglycemic events were avoided in both age groups by comprehensive management using SMBG. This study suggests the potential for safely improving poor glycemic control among elderly patients as well as non-elderly patients by initiating insulin therapy. However, 37.8% of non-elderly and 19.2% of elderly still experienced poor glycemic control (HbA1c ≥ 8.0%) after 1 year, and obesity was associated with poor glycemic control at 12 months in this study.

Although treatment strategies for elderly patients with diabetes mellitus are controversial, several intervention studies have reported the effectiveness of intensive treatment for elderly patients with diabetes \[[@CR14], [@CR15]\]. A 6-year interventional observational study conducted in Japan reported an association between high HbA1c levels and the development of retinopathy, and that intensive control of diabetes mellitus led to favorable outcomes \[[@CR14]\]. A study in Nagoya, Japan, found no increase in mortality among well-controlled elderly patients with diabetes compared to the general population after matching for age and sex \[[@CR15]\]. Thus, better management of diabetes might prevent and/or delay diabetic complications or improve mortality, despite minimal accumulated evidence in the elderly.

In general practice, improving uncontrolled diabetes in elderly patients is sometimes more difficult than in non-elderly patients because of age-related deterioration in glucose tolerance and a reduction in endogenous insulin secretion, and therefore treatment is likely to require insulin initiation in elderly patients with uncontrolled glycemic control \[[@CR16]\]. The Kumamoto study, a randomized controlled trial evaluating intervention with insulin therapy among 110 Japanese patients with uncontrolled type 2 diabetes, revealed the effectiveness of intensive treatment for primary and secondary prevention of diabetic complications, and showed that treatment with multiple insulin injections per day was more beneficial for total medical costs at 10 years of follow-up compared to a conventional insulin injection therapy \[[@CR17], [@CR18]\]. Although these studies were conducted in middle-aged patients (mean age, 48.2 years in multiple injection therapy group), the results may be applicable to elderly patients. Thus, adequate insulin initiation and maintaining safe insulin therapy is necessary for improving uncontrolled diabetes, and have a beneficial effect on healthcare expenditure.

Several reports have brought attention to excessively strict glycemic control strategies. The Diabetes and Aging Study, a large-scale retrospective cohort study of 71,092 patients in the United States with diabetes mellitus, reported that mortality had a U-shaped relationship with HbA1c, with an increased risk of all-cause mortality associated with HbA1c levels less than 6% \[[@CR19]\]. In the Health, Aging, and Body Composition Study, a prospective study conducted in the United States, insulin users with HbA1c levels ≤6.0% had a 4.36-fold higher risk of falls compared to those individuals with HbA1c levels ≥8.0% \[[@CR8]\]. In addition to the above-mentioned influences on mortality and morbidity, hypoglycemic events can trigger a series of complications \[[@CR8], [@CR20]\]. In a large-scale cohort study in the United States, patients with diabetes (mean age, 64.0 years) who experienced hypoglycemic events were 1.79 times more likely to experience an acute cardiovascular events than those who did not experience hypoglycemic events; similar results were also reported for patients aged ≥65 years compared to those for the entire population (odds ratio = 1.78) \[[@CR20]\]. In addition, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which was a randomized trial among diabetic patients aged 40--79 years with cardiovascular histories or their risks, showed that the risk of severe hypoglycemia in an intensive glycemic control group (HbA1c goal \< 6%) was more than threefold higher than in a standard glycemic control group (HbA1c goal 7.0--7.9%); furthermore, the mortality risk was 1.22-fold higher in the intensive compared to the standard glycemic control group \[[@CR7]\]. Therefore, avoidance of hypoglycemia is necessary for better glycemic control and to reduce mortality and morbidity. To avoid hypoglycemia in our study, we used SMBG, according to Japanese Diabetes Management Guidelines \[[@CR21]\], which involved regularly checking patient HbA1c levels and SMBG records, and modifying their treatment accordingly. No severe hypoglycemic events were observed in either the elderly or non-elderly groups during the 1-year follow-up period. SMBG may allow patients to evaluate their glucose concentrations and assess their achievement status to target glycemic levels \[[@CR5], [@CR22]\]. Therefore, comprehensive management that includes SMBG is a useful strategy for improving awareness and avoiding hypoglycemic events among insulin-treated elderly patients \[[@CR5], [@CR22]\]. In addition, the use of long-acting insulin may also avoid the problem of hypoglycemia in elderly patients. The APOLLO study, comparing once-daily basal insulin glargine (long-acting insulin) versus thrice-daily prandial insulin lispro (short-acting insulin) in 418 patients with type 2 diabetes aged 18--75 years, showed that hypoglycemic events were lower in the glargine treatment group than in the insulin lispro group (4.27 vs 19.46 per person) \[[@CR23]\]. On this basis it is therefore, important to consider the insulin type when initiating intensive insulin therapy in the elderly. To improve uncontrolled diabetes and prevent severe hypoglycemic events, treatment using insulin therapy can be acceptable as part of the comprehensive management for eligible patients who have the ability to use insulin therapy.

Although glycemic control was safely improved after initiation of insulin therapy in this study, 31.8% of non-elderly and 15.4% of elderly participants still experienced uncontrolled diabetes with HbA1c levels of at least 8%. Obese patients (BMI ≥ 25) were significantly more likely to have uncontrolled diabetes. During the 1-year follow-up period, body weight was significantly higher versus baseline at 12 months among non-elderly participants (66.1 vs 68.8 kg, *P* \< 0.01), but not among elderly participants (62.0 vs 63.2 kg, *P* = 0.10). It is possible that elderly participants may demonstrate healthier lifestyle behaviors related to avoid weight gain after initiation of insulin therapy \[[@CR3]\]. Obesity is a well-known risk factor for poor glycemic control, and the United Kingdom Prospective Diabetes Study (UKPDS 24), which was a randomized controlled trial among 4,075 patients aged 25--65 years with newly diagnosed type 2 diabetes including obese patients (48.2%), showed that initiating insulin therapy induced more hypoglycemia and weight gain without necessarily providing better glycemic control \[[@CR24]\]. Thus, both weight gain and hypoglycemia need to be addressed with adequate nutrition and exercise instruction.

There were several limitations to the present study. First, there may have been selection bias; the present study was conducted at one medical institution specializing in the treatment of diabetes. A large-scale multicenter study is needed to better compare our data to data from other medical settings. Second, this study did not include some important factors, in particular, social support, health behavior and nutrition status. Studies that obtain information regarding health behavior, nutrition status, and other related factors are needed. Third, our sample size was small. Similar to the first limitation, large-scale multicenter studies are required to address this issue. Fourth, differences existed in patient numbers, baseline HbA1c levels, type of insulin and dosage between the non-elderly and elderly patient groups. A large-scale study is required to adjust for these differences. Finally, 1 year is a relatively short study period. As a next step, cohort studies with long study periods (more than 5 years) are needed to assess long-term outcomes including glycemic control, onset of cardiovascular complications, mortality, and morbidity.

Conclusion {#Sec10}
==========

Our results indicate that newly initiated insulin therapy is as effective and safe for treating elderly Japanese patients with uncontrolled diabetes as for treating non-elderly patients. The study also clarified the utility of comprehensive management and education using SMBG to improve glycemic control and avoid hypoglycemia. The number of elderly patients with diabetes is expected to significantly increase not only in Japan, but worldwide too. Reducing morbidity and mortality requires improved glycemic control supported by adequate intensive management.
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